In a recent article, Sriram and collaborators (8) described a comparative study designed to detect Chlamydia pneumoniae DNA in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) or other neurological diseases (OND). Two PCR assays were performed on a common set of CSF samples at Vanderbilt University Medical Center (VUMC) and the University of South Florida (USF). The PCR assays, which targeted the ompA gene (or major outer membrane protein [MOMP] gene) of C. pneumoniae, were called VU-MOMP and USF-MOMP and were developed at the respective laboratories. A third assay, a nested-touchdown PCR targeting the same gene (10), was also performed at VUMC. Sriram et al. concluded that the results showed a high prevalence of C. pneumoniae in the CSF of MS patients. When the results of all the assays were combined, the overall detection rate was 83% in the clinically definite MS group, 57% in monosymptomatic MS patients, and significantly lower (16%; P Ͻ 0.01) in OND patients.
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In July 2002, the Centers for Disease Control and Prevention (CDC; Atlanta, Ga.) was contacted by the USF collaborators of the comparative study who were interested in testing DNA from peripheral blood mononuclear cells (PBMC) by their USF-MOMP PCR assay for C. pneumoniae. The investigators stated that this new USF-MOMP assay detected a high prevalence (more than 80%) of C. pneumoniae DNA in PBMC obtained from healthy donors. A total of 65 DNA samples extracted from human PBMC, rabbit PBMC, human placental DNA, human throat swabs, various bacterial species, and water were sent to the USF. All DNA samples had been previously assayed at the CDC, and no C. pneumoniae DNA was detected, except in one positive control (9) . Surprisingly, 23 (35%) of the DNA extracts were reported to be PCR positive at the USF; 21 (91%) of the positive samples were human PBMC. The samples were then assayed at the CDC using the USF-MOMP protocol. A PCR product was present in all samples considered positive at the USF, including the human placental negativecontrol DNA. However, the PCR product was clearly different in size than the product obtained by the amplification of C. pneumoniae DNA (ATCC VR1360) and was not considered positive. These facts indicate a probability that the primer set of the USF-MOMP protocol is nonspecific.
As mentioned by Sriram et al. (8) in the discussion section of the article, another collaborative study involving four laboratories had been conducted for the detection of C. pneumoniae DNA in the CSF of MS patients (5). VUMC found PCR evidence of C. pneumoniae in the CSF from 22 (73%) of 30 patients and 5 (23%) of 22 controls (P Ͻ 0.001), whereas the laboratories at the John's Hopkins University, Baltimore, Md., University Hospital of Umeå, Umeå, Sweden, and the CDC found no evidence for C. pneumoniae in any of the 52 CSF samples submitted. In a continuing effort to review current diagnostic tests for C. pneumoniae (2) , the CDC analyzed 19 of these 52 CSF specimens by using the VUMC protocols for DNA extraction and the VUMC PCR. VUMC claimed that the use of phenol-chloroform and dithiothreitol is critical for DNA extraction to ensure the solubilization of the cysteinerich outer membrane proteins of C. pneumoniae. None of the 19 CSF samples were positive for the presence of C. pneumoniae DNA when they were tested at the CDC. Instead, the agarose gel electrophoresis of the respective PCRs showed a large smear of DNA on the gel for 14 (73.6%) CSF samples. Thirteen of those samples had been previously reported to be PCR positive by the laboratory at VUMC. More importantly, amplification of human placental-control DNA (catalog no. D-3160; Sigma, St. Louis, Mo.) was detected as a band with a size similar to the VUMC's C. pneumoniae amplified product size. Although the set of primers used by Sriram et al. (8) is different than the one published previously (5, 7), both sets have a high sequence similarity to human DNA, as determined by BLAST search. These findings demonstrate the requirement for validation of C. pneumoniae PCR assays for specificity before their use on clinical samples.
There is considerable controversy concerning the evidence from PCR analysis for the presence of C. pneumoniae in the CSF of MS patients (1, (3) (4) (5) (6) (7) . Although other investigators have reported C. pneumoniae DNA in the CSF of MS and OND patients (4), we consider that the possibility of false-positive PCRs due to the amplification of human DNA still needs to be further investigated. In conclusion, large, multicenter collaborative studies are still necessary to confirm the possible involvement of C. pneumoniae in the pathogenesis of MS.
